# 2025-21702: FDA Drafts Rules to Detect Chemicals Leaching into Drugs

2025-21702, Q3E Guideline for Extractables and Leachables; International Council for Harmonisation; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-12-01, effective Notice published December 1, 2025; submit comments by January 30, 2026. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-21702
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-21702
- Title: Q3E Guideline for Extractables and Leachables; International Council for Harmonisation; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 55130
- Published: 2025-12-01
- Effective: Notice published December 1, 2025; submit comments by January 30, 2026.
- Comments close: 2026-01-30
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Drafts Rules to Detect Chemicals Leaching into Drugs

## Summary

The FDA just released a draft guide to help drug makers check for tiny chemicals that might sneak out of packaging or ingredients and into medicines. This new plan affects pharmaceutical companies by giving them clear, risk-based steps to keep medicines safe and high-quality. Comments are open until January 30, 2026, so companies should act fast to share their thoughts and prepare for possible changes that could impact costs and processes.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Q3E Guideline for Extractables and Leachables" and a draft supporting document entitled "Supporting Documentation: Class 3 Leachable Monographs." The draft guidance and supporting document were prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance presents a holistic framework and process for the assessment and control of extractables and leachables (E&L) for pharmaceutical products. The draft guidance builds upon ICH impurity guidances on new drug substances (ICH Q3A) and new drug products (ICH Q3B), residual solvents (ICH Q3C), and elemental impurities (ICH Q3D), as well as DNA reactive (mutagenic) impurities (ICH M7). In addition to outlining E&L safety assessment principles, the draft guidance includes draft supporting documentation of Class 3 leachable monographs. The draft guidance is intended to provide approaches to risk-based assessment and control of E&L to ensure patient safety and pharmaceutical product quality.

## Effects PRIA read

- ICH Q3E Draft Gives Global Framework: benefit, medium. The FDA published a draft ICH Q3E guidance on December 1, 2025 that gives drug makers a holistic, risk-based framework to assess and control extractables and leachables to help ensure patient safety and product quality. The ICH Assembly endorsed the draft in August 2025 and FDA is making it availab…
- New E&L Thresholds and Monographs: cost, medium. The draft guidance discusses thresholds for identifying, quantifying, and reporting extractables and leachables (E&L) and includes draft Class 3 leachable monographs in its supporting documentation. Drug makers will need to review these thresholds and monographs and may need to change testing, repo…
- Public Comment Deadline — Act Now: benefit, low. FDA requests comments on the draft Q3E guidance; comments must be submitted by January 30, 2026 for consideration before work on the final guidance. Companies that want to influence the final text or raise cost concerns should submit comments by that date.
- Draft Guidance Is Non-Binding, Final Will Consider Costs: benefit, low. The notice states FDA guidance documents are not legally enforceable and describe the Agency's current thinking; alternative approaches that satisfy statutes/regulations remain permitted. FDA also said it will consider comments on costs or cost savings (relevant to Executive Order 14192) as it deve…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-21702 on federalregister.gov](https://www.federalregister.gov/documents/2025/12/01/2025-21702/q3e-guideline-for-extractables-and-leachables-international-council-for-harmonisation-draft-guidance)
- [2025-21702 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-12-01/pdf/2025-21702.pdf)

## Related
- [Previous: 2025-21701, Combined Notice of Filings](https://policyrisk.com/federal-register/2025-21701)
- [Next: 2025-21703, Agency Information Collection Activity: Notice of Disagreement: Appeal to the B…](https://policyrisk.com/federal-register/2025-21703)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-21702 (as of 2026-06-08).
